| Revenue growth | 28.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | Consolidated EBITDA margin at 11.6%; excluding B2C, core margins at 14%. |
| Demand visibility | Strong momentum in HPPC (28%), TSC (28%), and AHN (27%) segments. |
| Management confidence | High; citing healthy momentum and robust domestic/international expansion. |
Growth
Revenue grew 28.2% YoY; EBITDA grew 18.7% YoY; PAT grew 4.5% YoY to Rs. 35.1 cr.
Outlook
New 5,000 MTPA Thailand facility commissioned; ongoing monetization of non-core assets; 15.2% FY26 revenue growth CAGR target.
Risks
Moderation in ROCE and ROE due to near-term investments; Institutional/B2C segments remained flat with negative EBITDA margins.
Last quarter's promises, checked
Delivered
- Guided 15% FY26 revenue growth → delivered 15% (= BEAT)
- Guided Q4 record revenue/EBITDA → delivered Rs 684.9 cr / Rs 77.3 cr (= BEAT)
- Guided Thailand plant commission by Q4 FY26 → delivered on stream March 2026 (= BEAT)
Partly delivered
- Guided Rs 192 cr CAPEX plan → rephased to Rs 50-75 cr for FY27 (= PARTIAL)
- Guided institutional breakeven → losses moderated but still negative (= PARTIAL)
Missed
- Guided 12-13% EBITDA margin → delivered 11.9% for FY26 (= MISS)
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹444.20
- Market cap
- ₹2,461 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 16.3×Sector 37.5×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech achieved highest-ever Q4 revenue and EBITDA in FY26, driven by 15% volume-led annual revenue growth. Focus is shifting toward high-margin pharma and oil & gas segments.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported highest-ever quarterly revenue of ₹684.9 cr and EBITDA of ₹77.3 cr in Q4 FY26. Performance driven by HPPC segment (77% of revenue) and capacity expansions.
Rossari Biotech Q4 FY26 Results: Net Profit ₹46 Cr, Up 33.7% YoY
Rossari Biotech Ltd reported revenue from operations of ₹684.9 Cr (+18.2% YoY) and net profit of ₹46 Cr (+33.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹46 Cr · +33.7% YoY